HLS Therapeutics Inc. (TSX:HLS)

HLS Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	55.5	56.62	63.07	61.47	60.01
Revenue Growth (YoY)	-1.98%	-10.23%	2.61%	2.43%	6.95%
Cost of Revenue	10.08	9	7.62	4.98	3.97
Gross Profit	45.42	47.62	55.45	56.49	56.04
Selling, General & Admin	27.71	32.59	33.86	35.58	32.06
Depreciation & Amortization Expenses	21.82	22.72	31.94	34.4	30.26
Other Operating Expenses	1.38	-2.4	6.22	5.19	0.17
Total Operating Expenses	50.9	52.91	72.02	75.17	62.49
Operating Income	-5.48	-5.29	-16.57	-18.68	-6.45
Interest Expense	-7.39	-10.29	-11.24	-5.04	-5.36
Total Non-Operating Income (Expense)	-7.39	-10.29	-11.24	-5.04	-5.36
Pretax Income	-12.88	-15.58	-27.8	-23.72	-11.81
Provision for Income Taxes	-0.45	4.07	-0.27	-0.12	1.31
Net Income	-12.43	-19.66	-27.53	-23.6	-13.12
Net Income to Common	-12.43	-19.66	-27.53	-23.6	-13.12
Shares Outstanding (Basic)	32	32	32	32	32
Shares Outstanding (Diluted)	32	32	32	32	32
Shares Change (YoY)	-0.98%	-1.31%	-0.52%	0.77%	1.48%
EPS (Basic)	-0.39	-0.62	-0.85	-0.73	-0.41
EPS (Diluted)	-0.39	-0.62	-0.85	-0.73	-0.41
Free Cash Flow	16.93	7.99	15.75	16.9	16.38
Free Cash Flow Growth	111.88%	-49.28%	-6.80%	3.14%	76.00%
Free Cash Flow Per Share	0.54	0.25	0.49	0.52	0.51
Dividends Per Share	-	-	0.076	0.148	0.158
Dividend Growth	-	-	-48.76%	-6.50%	0.69%
Gross Margin	81.83%	84.11%	87.91%	91.90%	93.38%
Operating Margin	-9.88%	-9.34%	-26.26%	-30.39%	-10.75%
Profit Margin	-22.40%	-34.71%	-43.65%	-38.39%	-21.86%
FCF Margin	30.50%	14.11%	24.97%	27.49%	27.30%
EBITDA	16.33	17.43	15.37	15.72	23.81
EBITDA Margin	29.43%	30.78%	24.37%	25.57%	39.68%
EBIT	-5.48	-5.29	-16.57	-18.68	-6.45
EBIT Margin	-9.88%	-9.34%	-26.26%	-30.39%	-10.75%
Effective Tax Rate	3.46%	-26.14%	0.98%	0.52%	-11.09%

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.